Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity

Phase IV head-to-head, double-blind trial comparing safety and efficacy met its primary and secondary endpointsThe DIRECTION trial results show ...
Colts Wire

URI study looks at using AR games to improve adoption of prostheses

Using augmented reality for prosthetic training can mimic rehabilitation therapy’s repetitive exercises and tap into the ...
Nasdaq

Ipsen Announces FDA Approval of Dysport® (abobotulinumtoxinA) for the Treatment of Upper Limb Spasticity in Children, Excluding Cerebral Palsy

– Dysport is the first and only FDA-approved botulinum toxin for treatment of both pediatric upper and lower limb spasticity1 – – Pivotal Phase 3 study demonstrated Dysport improved spasticity ...
The American Journal of Managed Care

Assessing Upper-Limb Function in Neuromuscular Diseases: Current Tools and Needs

A review of instruments used to assess upper-limb function in patients with neuromuscular diseases found that more tools are needed to address specific diseases. In most neuromuscular diseases (NMDs), ...
BMJ

646 MEP179 – What do upper-extremity physical performance tests measure? Insights from an electromyographical study

Background Upper-extremity physical performance tests (PPTs) are frequently employed for athletic screening because they are easily administered in field settings. Knowledge of muscle activity during ...